Cost-effectiveness analysis of a multicomponent meningococcal serogroup B vaccine in hypothetic epidemic situation in a middle-income country

Keyphrases

• Middle-income Countries 100%
• 4CMenB 100%
• Serogroup B Meningococcal Vaccine 100%
• Cost-effectiveness Analysis 100%
• Epidemic Situation 100%
• Chile 50%
• Mass Vaccination 50%
• Cost-effectiveness 33%
• Vaccine Cost 33%
• Epidemic Outbreak 33%
• Santiago De Chile 16%
• Vaccine Effectiveness 16%
• Immunogenicity 16%
• Acute Disease 16%
• Meningococcal Disease 16%
• Vaccination Strategy 16%
• Sensitivity Analysis 16%
• Indirect Costs 16%
• Direct Costs 16%
• Intervention Strategies 16%
• One Dose 16%
• Vaccine Dose 16%
• Disease Sequelae 16%
• Vaccine Introduction 16%
• Bellows 16%
• Multiple Interventions 16%
• Acute Death 16%
• Individual Cost 16%
• Disease-based 16%

Medicine and Dentistry

• Health Care Cost 100%
• Cost-Effectiveness Analysis 100%
• Serotype 100%
• Sequela 33%
• Mass Immunization 33%
• Epidemic 11%
• Meningococcal Disease 11%
• Immunogenicity 11%
• Acute Disease 11%

Pharmacology, Toxicology and Pharmaceutical Science

• Vaccination Policy 100%
• Epidemic 33%
• Immunogenicity 33%
• Meningococcosis 33%
• Acute Disease 33%